Phase 2 Breast Cancer Trial, Recruiting NCT07335081 Sponsor: Shanghai Jiao Tong University School of Medicine Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT07335081
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Stage II or Stage III HER2-positive breast cancer, confirmed by a tissue sample, with a tumour larger than 2cm
  • You are generally able to carry out daily activities with little to no limitation (as assessed by your doctor using a standard scale)
  • Your kidneys, liver, bone marrow, and heart are all functioning well, including a heart pumping strength of at least 55% as measured by an ultrasound of the heart
  • You have not received any previous treatment for this condition

Who may not be able to join:

  • You have breast cancer in both breasts, or the cancer has spread to other parts of the body
  • You have a history of any other type of cancer
  • You have a serious heart or cardiovascular condition
  • You have a known allergy to any of the medications used in this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86 18817865256

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
1 February 2024
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

ctDNA clearance after one cycle neoadjuvant treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov